Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors

被引:451
作者
Zolotukhin, S
Potter, M
Zolotukhin, I
Sakai, Y
Loiler, S
Fraites, TJ
Chiodo, VA
Phillipsberg, T
Muzyczka, N
Hauswirth, WW
Flotte, TR
Byrne, BJ
Snyder, RO
机构
[1] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA
[4] Univ Florida, Coll Med, Dept Opthamol, Gainesville, FL 32610 USA
关键词
adeno-associated virus; gene therapy; chromatography; purification; serotype;
D O I
10.1016/S1046-2023(02)00220-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant adeno-associated viral (rAAV) vectors based on serotype 2 are currently being evaluated most extensively in animals and human clinical trials. rAAV vectors constructed from other AAV serotypes (scrota pes 1, 3, 4, 5 and 6) can transduce certain tissues more efficiently and with different specificity than rAAV2 vectors in animal models. Here, e describe reagents and methods for the production and purification of AAV2 inverted terminal repeat-Containing vectors pseudotyped with AAV1 or AAV5 capsids. To facilitate pseudotyping, AAV2rep/AAV1cap and AAV2rep/AAV5cap helper plasmids were constructed in an adenoviral plasmid backbone. The resultant plasmids, pXYZ1 and pXYZ5. were used to produce rAAV1 and rAAV5 vectors. respectively, by transient transfection. Since neither AAV5 nor AAV1 binds to the heparin affinity chromatography resin used to purify rAAV2 vectors, purification protocols were developed based on anion-exchange chromatography. The purified vector stocks are 99% pure with titers of 1 X 10(12) to 1 X 10(13) vector genomes/ml. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:158 / 167
页数:10
相关论文
共 52 条
[1]   A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors [J].
Auricchio, A ;
O'Connor, E ;
Hildinger, M ;
Wilson, JM .
MOLECULAR THERAPY, 2001, 4 (04) :372-374
[2]  
Chadeuf G, 2000, J GENE MED, V2, P260
[3]   Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors [J].
Chao, HJ ;
Liu, YB ;
Rabinowitz, J ;
Li, CW ;
Samulski, RJ ;
Walsh, CE .
MOLECULAR THERAPY, 2000, 2 (06) :619-623
[4]   Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles [J].
Chiorini, JA ;
Yang, L ;
Liu, YJ ;
Safer, B ;
Kotin, RM .
JOURNAL OF VIROLOGY, 1997, 71 (09) :6823-6833
[5]   Cloning and characterization of adeno-associated virus type 5 [J].
Chiorini, JA ;
Kim, F ;
Yang, L ;
Kotin, RM .
JOURNAL OF VIROLOGY, 1999, 73 (02) :1309-1319
[6]  
Clark KR, 1996, GENE THER, V3, P1124
[7]  
Clarke J. M., 1913, Mon serv geol min Brasil, V1, pUnpaginated
[8]   High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap [J].
Conway, JE ;
ap Rhys, CMJ ;
Zolotukhin, I ;
Zolotukhin, S ;
Muzyczka, N ;
Hayward, GS ;
Byrne, BJ .
GENE THERAPY, 1999, 6 (06) :986-993
[9]   Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system [J].
Davidson, BL ;
Stein, CS ;
Heth, JA ;
Martins, I ;
Kotin, RM ;
Derksen, TA ;
Zabner, J ;
Ghodsi, A ;
Chiorini, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3428-3432
[10]   Adeno-associated virus site-specifically integrates into a muscle-specific DNA region [J].
Dutheil, N ;
Shi, F ;
Dupressoir, T ;
Linden, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) :4862-4866